Key Endocannabinoid 2-AG Is Depleted in Rheumatoid and Osteoarthritis Patients

Among 80 participants (25 RA, 18 OA, 37 healthy), 2-arachidonoylglycerol (2-AG) levels were significantly lower in both RA and OA patients compared to controls. RA patients also had higher ethanolamide-type endocannabinoids (anandamide, DHA-EA, etc.) and lower levels of the pro-resolving lipid 9-oxoODE and omega-3 fatty acids EPA and DHA.

Clinical study of 80 participants comparing 16 endocannabinoids/congeners and 129 oxylipins in plasma using LC-MS/MS assays across RA patients, OA patients, and healthy controls.

2-AG is a critical regulator of pain signaling and inflammation. Finding it depleted in arthritis suggests a specific endocannabinoid deficiency that could help explain residual pain and points toward targeted cannabinoid therapies.

The endocannabinoid deficiency theory proposes that low endocannabinoid levels contribute to chronic pain conditions. This study provides direct evidence of 2-AG depletion in two major forms of arthritis, supporting this theory and suggesting why exogenous cannabinoids might help.

Small sample sizes per group. Cross-sectional design cannot determine whether low 2-AG causes arthritis symptoms or results from them. Plasma levels may not reflect tissue-level endocannabinoid concentrations at joint sites.